RecruitingPhase 4ACTRN12608000476336

International Study to Predict Optimized Treatment - in Depression

International Study to Predict Optimized Treatment response to the three most commonly used antidepressants (Escitalopram, Sertraline and Venlafaxine extended release XR,) in subjects diagnosed with major depressive disorder (MDD) as compared to matched healthy controls.

Sponsor

Brain Resource

Enrollment

2,688 participants

Start Date

Jul 15, 2008

Study Type

Interventional

Conditions

Major Depressive Disorder (MDD)

Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 65 Yearss

Inclusion Criteria1

Meet Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)criteria for primary Major Depressive Disorder with a Hamilton Rating Depression Scale (HAM-D) score >/= 16 and who are fluent in English or Dutch.

Exclusion Criteria4

Presence of suicidal ideations, biopoloar, psychosis or primary eating disorder.
Prior or resent use antidepressants including escitalopram, sertraline, venlafaxine XR.
History of brain injury/blow resulting in loss of consciousness.
evere impediment to vision, hearing and/or hand movement which may interfere with their ability to complete the protocol required test.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Once randomised and on drug, subjects will be dosed with study medication as per local/country standard of care. Therefore, the length of treatment will differ and is based on the subjects response.

Once randomised and on drug, subjects will be dosed with study medication as per local/country standard of care. Therefore, the length of treatment will differ and is based on the subjects response. escitalopram one 10 mg tablet orally once daily (QD) sertraline one 50 mg orally QD venlafaxine extended release (XR) one 75 mg orally QD